Recombinant Therapeutic Proteins Market & Pipeline Analysis
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
Proteins are known to be the building blocks of life, and as a part of the natural metabolism, they are synthesized by all living forms. Some proteins, such as enzymes, tend to serve as biocatalysts, which help in increasing the rate of metabolic reactions. There are other types of proteins which form the cytoskeleton. There is a significant role played by proteins in functions like cell signaling, immune responses, cell adhesion, and the cell cycle. In industries, proteins are commercially produced by using genetic engineering and protein engineering. There are many sectors such as the biopharmaceutical industry, the enzyme industry, and the agricultural industry, which are significantly benefitted from native and recombinant proteins. In return the products manufactured in these industries tend to support the fields of medicine, diagnostics, food, nutrition, detergents, textiles, leather, paper, pulp, polymers and plastics.
Recombinant protein is a modified version of protein which is produced through different methods in order to further generate large quantities of proteins, modify gene sequences and eventually manufactures commercial products. The recombinant protein is formed with the help of specialized vehicles which are called vectors. The recombinant technology is the entire process which is involved in the formation of a recombinant protein.
Generally, the therapeutic proteins include antibody-based drugs, anticoagulants, blood factors, bone morphogenetic proteins, engineered protein scaffolds, enzymes, Fc fusion proteins, growth factors, hormones, interferons, interleukins, and thrombolytic. Of the total biopharmaceuticals which is being currently marketed, the dominant segment is accounted for by the recombinant therapeutic protein drugs. The major areas of applications are diabetes, dwarf¬ism, myocardial infarction, congestive heart failure, cerebral apoplexy, multiple sclerosis, neutropenia, thrombocytopenia, anemia, hepatitis, rheumatoid arthritis, asthma, Crohn’s disease and cancers therapies.
There are many driving forces for the recombinant proteins market. These include the introduction of new protein therapeutics and enhanced investments which are likely to significantly impact the growth of this industry in a positive manner. Additionally, the rapidly rising number of clinical trials would also help in surfacing the optimistic performance of the industry.
In terms of segments, the major revenue-generating segments of the recombinant therapeutic protein market include monoclonal antibody, Insulin, Interferon Beta, G-CSF and coagulation factors. At present, owing to the fact that large number of companies is focusing their efforts in developing innovative treatment options using mAbs, this segment is currently the most dominant in terms of growth rate. In terms of the regional scenario of the recombinant proteins market, it has been observed that the US has been and would continue to account for the largest share of the global pie followed by the European countries. The emerging nations which are likely to be the future revenue generators for this market include the Asian and Middle-Eastern region, which is having a growing therapeutic market owing to improving economic scenario and financial capability of people.
The future years are likely to witness the protein therapeutics and specifically recombinant proteins dominating the overall pharmaceutical industry. Though in terms of market size, the protein therapeutics market is significantly smaller than the overall pharmaceutical market, on a comparative basis, the growth of the protein therapeutics market is significantly higher than the growth of the overall pharmaceutical market. With the introduction and increasing adoption of “recombinant technology”, it is most likely that the protein therapeutics market would flourish in the coming years. This technology involves the development of therapies through designing the required protein structure synthetically. There is considerable amount of research being done in this field by both the private companies and the academicians and researchers at the universities and research centers. Their efforts are being directed towards successfully develop protein-based therapies for curing diseases like HIV/AIDS, cancer, hormonal imbalance and neurological disorders. Further, because of advantages like their higher specificity and effectiveness as compared to other drug forms, the protein therapies have become highly attractive for the pharmaceuticals companies who are rapidly shifting their focus towards this field.
“Recombinant Therapeutic Proteins Market & Pipeline Analysis” Report Highlights:
Proteins are known to be the building blocks of life, and as a part of the natural metabolism, they are synthesized by all living forms. Some proteins, such as enzymes, tend to serve as biocatalysts, which help in increasing the rate of metabolic reactions. There are other types of proteins which form the cytoskeleton. There is a significant role played by proteins in functions like cell signaling, immune responses, cell adhesion, and the cell cycle. In industries, proteins are commercially produced by using genetic engineering and protein engineering. There are many sectors such as the biopharmaceutical industry, the enzyme industry, and the agricultural industry, which are significantly benefitted from native and recombinant proteins. In return the products manufactured in these industries tend to support the fields of medicine, diagnostics, food, nutrition, detergents, textiles, leather, paper, pulp, polymers and plastics.
Recombinant protein is a modified version of protein which is produced through different methods in order to further generate large quantities of proteins, modify gene sequences and eventually manufactures commercial products. The recombinant protein is formed with the help of specialized vehicles which are called vectors. The recombinant technology is the entire process which is involved in the formation of a recombinant protein.
Generally, the therapeutic proteins include antibody-based drugs, anticoagulants, blood factors, bone morphogenetic proteins, engineered protein scaffolds, enzymes, Fc fusion proteins, growth factors, hormones, interferons, interleukins, and thrombolytic. Of the total biopharmaceuticals which is being currently marketed, the dominant segment is accounted for by the recombinant therapeutic protein drugs. The major areas of applications are diabetes, dwarf¬ism, myocardial infarction, congestive heart failure, cerebral apoplexy, multiple sclerosis, neutropenia, thrombocytopenia, anemia, hepatitis, rheumatoid arthritis, asthma, Crohn’s disease and cancers therapies.
There are many driving forces for the recombinant proteins market. These include the introduction of new protein therapeutics and enhanced investments which are likely to significantly impact the growth of this industry in a positive manner. Additionally, the rapidly rising number of clinical trials would also help in surfacing the optimistic performance of the industry.
In terms of segments, the major revenue-generating segments of the recombinant therapeutic protein market include monoclonal antibody, Insulin, Interferon Beta, G-CSF and coagulation factors. At present, owing to the fact that large number of companies is focusing their efforts in developing innovative treatment options using mAbs, this segment is currently the most dominant in terms of growth rate. In terms of the regional scenario of the recombinant proteins market, it has been observed that the US has been and would continue to account for the largest share of the global pie followed by the European countries. The emerging nations which are likely to be the future revenue generators for this market include the Asian and Middle-Eastern region, which is having a growing therapeutic market owing to improving economic scenario and financial capability of people.
The future years are likely to witness the protein therapeutics and specifically recombinant proteins dominating the overall pharmaceutical industry. Though in terms of market size, the protein therapeutics market is significantly smaller than the overall pharmaceutical market, on a comparative basis, the growth of the protein therapeutics market is significantly higher than the growth of the overall pharmaceutical market. With the introduction and increasing adoption of “recombinant technology”, it is most likely that the protein therapeutics market would flourish in the coming years. This technology involves the development of therapies through designing the required protein structure synthetically. There is considerable amount of research being done in this field by both the private companies and the academicians and researchers at the universities and research centers. Their efforts are being directed towards successfully develop protein-based therapies for curing diseases like HIV/AIDS, cancer, hormonal imbalance and neurological disorders. Further, because of advantages like their higher specificity and effectiveness as compared to other drug forms, the protein therapies have become highly attractive for the pharmaceuticals companies who are rapidly shifting their focus towards this field.
“Recombinant Therapeutic Proteins Market & Pipeline Analysis” Report Highlights:
- Global Market Overview
- Mechanisms of Recombinant Protein Production
- Types of Recombinant DNA Technology
- Clinical Pipeline by Phase, Indication, Company, & Country
- Marketed Recombinant Therapeutic Protein Drugs Clinical Insight
- Recombinant Therapeutic Proteins Clinical Pipeline: 340 Drugs
- Marketed Recombinant Therapeutic Protein Drugs : 83 Drugs
- Majority Recombinant Therapeutic Proteins in Preclinical Phase: 128 Drugs
1. WHAT ARE RECOMBINANT PROTEINS?
1.1 Recombinant Proteins Overview
1.2 History of Recombinant Proteins
2. WHY THERE EXIST NEED FOR RECOMBINANT PROTEINS?
3. DIFFERENT TYPES OF RECOMBINANT DNA TECHNOLOGY
4. MECHANISMS OF RECOMBINANT PROTEIN PRODUCTION
4.1 Recombinant Protein Production & Expression
4.2 Different Methods of Protein Production
4.3 Process for Producing Recombinant Proteins
5. GLOBAL RECOMBINANT THERAPEUTIC PROTEINS MARKET OVERVIEW
5.1 Current Market Scenario
5.2 Recombinant Proteins Clinical Pipeline Overview
6. GLOBAL RECOMBINANT THERAPEUTIC PROTEINS MARKET DYNAMICS
6.1 Market Drivers
6.2 Challenges
7. RECOMBINANT THERAPEUTIC PROTEINS MARKET FUTURE GROWTH OUTLOOK
8. RECOMBINANT THERAPEUTIC PROTEINS CLINICAL PIPELINE BY PHASE, INDICATION, COMPANY, & COUNTRY
8.1 Research till Registration
8.2 Marketed Recombinant Therapeutic Protein Drugs
8.3 Suspended & Discontinued Drugs in Clinical Pipeline
9. RECOMBINANT ERYTHROPOIETINS CLINICAL PIPELINE BY PHASE, INDICATION, COMPANY, & COUNTRY
9.1 Research till Registration
9.2 Marketed Recombinant Erythropoietin Drugs
9.3 Suspended & Discontinued Drugs in Clinical Pipeline
10. RECOMBINANT THERAPEUTIC FUSION PROTEINS CLINICAL PIPELINE BY PHASE, INDICATION, COMPANY, & COUNTRY
10.1 Research till Registration
10.2 Marketed Recombinant Fusion Protein Drugs
10.3 Suspended & Discontinued Drugs in Clinical Pipeline
11. COMPETITIVE LANDSCAPE
11.1 Boehringer Ingelheim
11.2 Bristol-Myers Squibb
11.3 Celldex Therapeutics
11.4 Eli Liily
11.5 GlaxoSmithKline
11.6 Merck
11.7 Novartis
11.8 Regeneron Pharmaceuticals
11.9 Roche
11.10 Shire Pharmaceuticals
1.1 Recombinant Proteins Overview
1.2 History of Recombinant Proteins
2. WHY THERE EXIST NEED FOR RECOMBINANT PROTEINS?
3. DIFFERENT TYPES OF RECOMBINANT DNA TECHNOLOGY
4. MECHANISMS OF RECOMBINANT PROTEIN PRODUCTION
4.1 Recombinant Protein Production & Expression
4.2 Different Methods of Protein Production
4.3 Process for Producing Recombinant Proteins
5. GLOBAL RECOMBINANT THERAPEUTIC PROTEINS MARKET OVERVIEW
5.1 Current Market Scenario
5.2 Recombinant Proteins Clinical Pipeline Overview
6. GLOBAL RECOMBINANT THERAPEUTIC PROTEINS MARKET DYNAMICS
6.1 Market Drivers
6.2 Challenges
7. RECOMBINANT THERAPEUTIC PROTEINS MARKET FUTURE GROWTH OUTLOOK
8. RECOMBINANT THERAPEUTIC PROTEINS CLINICAL PIPELINE BY PHASE, INDICATION, COMPANY, & COUNTRY
8.1 Research till Registration
8.2 Marketed Recombinant Therapeutic Protein Drugs
8.3 Suspended & Discontinued Drugs in Clinical Pipeline
9. RECOMBINANT ERYTHROPOIETINS CLINICAL PIPELINE BY PHASE, INDICATION, COMPANY, & COUNTRY
9.1 Research till Registration
9.2 Marketed Recombinant Erythropoietin Drugs
9.3 Suspended & Discontinued Drugs in Clinical Pipeline
10. RECOMBINANT THERAPEUTIC FUSION PROTEINS CLINICAL PIPELINE BY PHASE, INDICATION, COMPANY, & COUNTRY
10.1 Research till Registration
10.2 Marketed Recombinant Fusion Protein Drugs
10.3 Suspended & Discontinued Drugs in Clinical Pipeline
11. COMPETITIVE LANDSCAPE
11.1 Boehringer Ingelheim
11.2 Bristol-Myers Squibb
11.3 Celldex Therapeutics
11.4 Eli Liily
11.5 GlaxoSmithKline
11.6 Merck
11.7 Novartis
11.8 Regeneron Pharmaceuticals
11.9 Roche
11.10 Shire Pharmaceuticals
LIST OF FIGURES
Figure 1-1: Most Commonly Used Recombinant Protein Products
Figure 1-2: Biopharmaceutical Approval in European Union & US During 2008-2013
Figure 3-1: Recombinant DNA Technologies
Figure 4-1: Process for Producing Recombinant Proteins
Figure 5-1: Global Biologics Market Classification
Figure 5-2: Global Protein Therapeutics Market (US$ Billion), 2013-2020
Figure 5-3: Global Therapeutic Protein Market by Region (%), 2014
Figure 5-4: Share of Producing Agents for Recombinant Proteins, 2014
Figure 5-5: Recombinant Therapeutic Proteins Clinical Pipeline by Phase (%), 2014
Figure 5-6: Recombinant Therapeutic Proteins Clinical Pipeline by Phase (Number), 2014
Figure 5-7: No Development Reported in Recombinant Therapeutic Proteins Clinical Pipeline by Phase (%), 2014
Figure 5-8: No Development Reported in Recombinant Therapeutic Proteins Clinical Pipeline by Phase (Number), 2014
Figure 5-9: Discontinued Recombinant Therapeutic Proteins Clinical Pipeline by Phase (%), 2014
Figure 5-10: Discontinued Recombinant Therapeutic Proteins Clinical Pipeline by Phase (Number), 2014
Figure 5-11: Suspended Recombinant Therapeutic Proteins Clinical Pipeline by Phase (%), 2014
Figure 5-12: Suspended Recombinant Therapeutic Proteins Clinical Pipeline by Phase (Number), 2014
Figure 5-13: Recombinant Erythropoietins Clinical Pipeline by Phase (%), 2014
Figure 5-14: Recombinant Erythropoietins Clinical Pipeline by Phase (Number), 2014
Figure 5-15: Discontinued Recombinant Erythropoietins Clinical Pipeline by Phase (%), 2014
Figure 5-16: Discontinued Recombinant Erythropoietins Clinical Pipeline by Phase (Number), 2014
Figure 5-17: Recombinant Therapeutic Fusion Proteins Clinical Pipeline by Phase (%), 2014
Figure 5-18: Recombinant Therapeutic Fusion Proteins Clinical Pipeline by Phase (Number), 2014
Figure 5-19: No Development Reported in Recombinant Therapeutic Fusion Proteins Clinical Pipeline by Phase (%), 2014
Figure 5-20: No Development Reported in Recombinant Therapeutic Fusion Proteins Clinical Pipeline by Phase (Number), 2014
Figure 5-21: Discontinued Recombinant Therapeutic Fusion Proteins Clinical Pipeline by Phase (%), 2014
Figure 5-22: Discontinued Recombinant Therapeutic Fusion Proteins Clinical Pipeline by Phase (Number), 2014
Figure 1-1: Most Commonly Used Recombinant Protein Products
Figure 1-2: Biopharmaceutical Approval in European Union & US During 2008-2013
Figure 3-1: Recombinant DNA Technologies
Figure 4-1: Process for Producing Recombinant Proteins
Figure 5-1: Global Biologics Market Classification
Figure 5-2: Global Protein Therapeutics Market (US$ Billion), 2013-2020
Figure 5-3: Global Therapeutic Protein Market by Region (%), 2014
Figure 5-4: Share of Producing Agents for Recombinant Proteins, 2014
Figure 5-5: Recombinant Therapeutic Proteins Clinical Pipeline by Phase (%), 2014
Figure 5-6: Recombinant Therapeutic Proteins Clinical Pipeline by Phase (Number), 2014
Figure 5-7: No Development Reported in Recombinant Therapeutic Proteins Clinical Pipeline by Phase (%), 2014
Figure 5-8: No Development Reported in Recombinant Therapeutic Proteins Clinical Pipeline by Phase (Number), 2014
Figure 5-9: Discontinued Recombinant Therapeutic Proteins Clinical Pipeline by Phase (%), 2014
Figure 5-10: Discontinued Recombinant Therapeutic Proteins Clinical Pipeline by Phase (Number), 2014
Figure 5-11: Suspended Recombinant Therapeutic Proteins Clinical Pipeline by Phase (%), 2014
Figure 5-12: Suspended Recombinant Therapeutic Proteins Clinical Pipeline by Phase (Number), 2014
Figure 5-13: Recombinant Erythropoietins Clinical Pipeline by Phase (%), 2014
Figure 5-14: Recombinant Erythropoietins Clinical Pipeline by Phase (Number), 2014
Figure 5-15: Discontinued Recombinant Erythropoietins Clinical Pipeline by Phase (%), 2014
Figure 5-16: Discontinued Recombinant Erythropoietins Clinical Pipeline by Phase (Number), 2014
Figure 5-17: Recombinant Therapeutic Fusion Proteins Clinical Pipeline by Phase (%), 2014
Figure 5-18: Recombinant Therapeutic Fusion Proteins Clinical Pipeline by Phase (Number), 2014
Figure 5-19: No Development Reported in Recombinant Therapeutic Fusion Proteins Clinical Pipeline by Phase (%), 2014
Figure 5-20: No Development Reported in Recombinant Therapeutic Fusion Proteins Clinical Pipeline by Phase (Number), 2014
Figure 5-21: Discontinued Recombinant Therapeutic Fusion Proteins Clinical Pipeline by Phase (%), 2014
Figure 5-22: Discontinued Recombinant Therapeutic Fusion Proteins Clinical Pipeline by Phase (Number), 2014
LIST OF TABLES
Table 1-1: First Generation of Therapeutic Proteins
Table 1-2: Second Generation of Therapeutic Proteins
Table 1-3: Monoclonal Antibodies
Table 1-1: First Generation of Therapeutic Proteins
Table 1-2: Second Generation of Therapeutic Proteins
Table 1-3: Monoclonal Antibodies
